Skip to main content
Premium Trial:

Request an Annual Quote

Vela Dx Collaborates With Gustave Roussy on Solid and Liquid Tumor Testing

NEW YORK (GenomeWeb) – Vela Diagnostics today announced a collaboration with France's Gustave Roussy Institute of Oncology on next-generation based cancer testing.

The collaboration will focus on both solid and liquid tumor diagnostics using Vela's Sentosa NGS platform. Gustave Roussy, located just outside Paris, recently implemented the Sentosa platform to diagnose melanoma, colorectal cancer, and non-small cell lung cancer.

Sentosa is a CE-marked, fully automated NGS platform for routine diagnostic use. Vela launched the Sentosa SQ Colorectal Cancer panel in January. The firm said in a statement that it expects to launch additional tests for leukemia and infectious disease on the Sentosa platform.

The collaboration is the latest positive development for Singapore-based Vela. In September, the firm resumed operations as it exited judicial management — a legal process similar to Chapter 11 bankruptcy. Vela had ceased normal operations upon entering the process in early 2015.